CIVILICA We Respect the Science
Publisher of Iranian Journals and Conference Proceedings
Paper
title

Involvement of MIR4301 in the DRD2 mediated tumor growth by in-silico analysis

Credit to Download: 0 | Page Numbers 1 | Abstract Views: 122
Year: 2016
COI code: IPMCMED01_114
Paper Language: English

How to Download This Paper

For Downloading the Fulltext of CIVILICA papers please visit the orginal Persian Section of website.

Authors Involvement of MIR4301 in the DRD2 mediated tumor growth by in-silico analysis

  Naghmeh Gholipour - national institute of genetic engineering and biotechnology (nigeb), tehran, iran
  Ghasem Ahangari - national institute of genetic engineering and biotechnology (nigeb), tehran, iran

Abstract:

Background: Various types of neoplasms including breast cancer exhibit of different profile changes in both mRNA and micro-RNA expression. The dopamine receptors are dysregulated in various human cancers, but the molecular mechanisms underlying dopamine receptors mediated tumor growth remain unclear. Here we examined the involvement of MIR4301 in the DRD2 mediated tumor growth by in-silico analysis.Methods: To determine the gene targets of the differentially expressed miRNAs, we used three of the leading miRNA target prediction algorithms: mirwalk2, PicTar, and TargetScan. Mirwalk2 found the miRNA-target genes in the Carcinogenesis pathway and verified by KEGG pathways. KEGG pathway is derived from Kanehisa Lab, Kyoto University, Japan. This analysis is used to determine the position and role of this MIR4301 in controling carcinogenesis pathway. The position and function of genes in a pathway are crucial for recognizing the mechanism of intervention or regulation of MIR4301 in carcinogenesis.We aligned DRD2 (ENST00000362072) and MIR4301 in NCBI database and found that this MIR located within the DRD2 intronic region. Structural and stability analysis of MIR4301 was conducted by using the online application Mfold.Results: By using three target prediction tools, 9882 candidate genes were predicted for MIR4301 and all the predicted candidate genes were analyzed by pathways enriched analysis. KEGG and Panther pathways enrichment analysis showed that 36417 endometriosis-related miRNA targets were mainly cancer-related pathways RAS and PI3K pathway.Conclusions: MIR 4301 is a 65 base-pair long non-coding RNA localized in chromosome 11 (nt: 113450023-113450088). Bioinformatics analysis has showed, DRD2 can be a potential target of MIR4301and suggested the probable effect of this microRNA in the regulation of DRD2 expression.

Keywords:

MIR4301, DRD2, cancer

Perma Link

https://www.civilica.com/Paper-IPMCMED01-IPMCMED01_114.html
COI code: IPMCMED01_114

how to cite to this paper:

If you want to refer to this article in your research, you can easily use the following in the resources and references section:
Gholipour, Naghmeh & Ghasem Ahangari, 2016, Involvement of MIR4301 in the DRD2 mediated tumor growth by in-silico analysis, First Personal Medical Congress, تهران, دانشگاه علوم پزشكي ايران - پژوهشكده ملي مهندسي ژنتيك و زيست فناوري ايران، مركز همكاري هاي فناوري و نوآوري هاي رياست جمهوري, https://www.civilica.com/Paper-IPMCMED01-IPMCMED01_114.htmlInside the text, wherever referred to or an achievement of this article is mentioned, after mentioning the article, inside the parental, the following specifications are written.
First Time: (Gholipour, Naghmeh & Ghasem Ahangari, 2016)
Second and more: (Gholipour & Ahangari, 2016)
For a complete overview of how to citation please review the following CIVILICA Guide (Citation)

Scientometrics

The University/Research Center Information:
in University Ranking and Scientometrics the Iranian universities and research centers are evaluated based on scientific papers.

Research Info Management

Export Citation info of this paper to research management softwares

New Related Papers

Iran Scientific Advertisment Netword

Share this paper

WHAT IS COI?

COI is a national code dedicated to all Iranian Conference and Journal Papers. the COI of each paper can be verified online.